Tempus’ FOLR1 testing is recommended for patients with fallopian tube, epithelial ovarian, or primary peritoneal cancer. Credit: New Africa / Shutterstock.

Technology company Tempus has introduced new testing solutions to help identify patients with HER2 or FOLR1-expressing tumours.

The new HER2 and FOLR1 testing solutions will help identify patients eligible for targeted therapies such as antibody-drug conjugates (ADCs).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Tempus said the HER2 and FOLR1 testing by immunohistochemistry (IHC), as an add-on to the company’s xT or xR next-generation sequencing assays, is made available for all solid tumour cancers.

The two IHC tests are recommended in clinical guidelines for several types of cancers. It can also be ordered for other cancer types at the clinician’s discretion.

Tempus noted that FOLR1 testing is recommended for patients, who have epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Tempus oncology chief medical officer Ezra Cohen said: “Expanding our offerings to include tests for specific, predictive biomarkers, like HER2, can help reveal a patient’s responsiveness to therapies that have the potential to positively impact their outcome.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“These are the kind of critical tools that we are arming physicians with as new, targeted therapies are made available for patients.”

In a separate announcement, Tempu and AstraZeneca have expanded their partnership, utilising Tempus Next to provide doctors with technology that facilitates the administration of guideline-directed biomarker testing for patients suffering from non-small cell lung cancer (NSCLC). 

The two companies are currently building on a pilot programme that uses Next, Tempus’ care pathway intelligence platform, to help doctors decide whether to recommend guideline-directed molecular testing for patients with NSCLC, which includes testing for epidermal growth factor receptor (EGFR) mutations.

Additionally, Tempus has announced the clinical launch of its minimal residual disease test portfolio – the Tempus xM test and the xM (NeXT Personal Dx) test by Personalis.

This portfolio comprises both a tumour-naïve assay and a tumour-informed assay, which can identify residual disease or early cancer recurrence and monitor immunotherapy treatment response.

These tests provide valuable insights to inform patient management strategies.